Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women.

[en] The results of this study suggested that long-term treatment with strontium ranelate over 5 years is cost-effective compared to no treatment for postmenopausal osteoporotic women. INTRODUCTION: This study aims to estimate the cost-effectiveness of long-term strontium ranelate treatment for postmenopausal osteoporotic women. METHODS: A validated Markov microsimulation model with a Belgian healthcare cost perspective was used to assess the cost per quality-adjusted life-year (QALY) of strontium ranelate compared to no treatment, on a basis of calcium/vit D supplementation if needed. Analyses were performed for women aged 70, 75, and 80 years either with a bone mineral density T-score 15,096 and 6,913 at 70 and 75 years of age while these values were 23,426 and 9,698 for women with prevalent vertebral fractures. Sensitivity analyses showed that the results were robust over a wide range of assumptions. CONCLUSION: This study suggested that, compared to no treatment, long-term strontium ranelate treatment is cost-effective for postmenopausal osteoporotic women.

Disciplines :

Rheumatology
Special economic topics (health, labor, transportation...)

Author, co-author :

Hiligsmann, Mickaël ; Université de Liège - ULiège > HEC - École de gestion de l'ULiège > Economie industrielle

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique - Département des sciences de la santé publique

Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique

Language :

English

Title :

Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women.

Publication date :

2010

Journal title :

Osteoporosis International

ISSN :

0937-941X

eISSN :

1433-2965

Publisher :

Springer Science & Business Media B.V., Godalming, United Kingdom

Volume :

Pages :

157-165

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 06 May 2009

Statistics

Number of views

518 (15 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

1. Boonen S, Body JJ, Boutsen Y et al (2005) Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16:239-254 (Pubitemid 40379423)
Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture, N Engl J Med 357:1799-1809, nihpa40967
Harris ST, Reginster JY, Harley C et al (2009) Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The evaluation of IBandronate Efficacy (VIBE) database fracture study. Bone. doi:10.1016/j.bone.2009.01.002
4. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium, ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468 (Pubitemid 38133766)
5. Reginster JY, Felsenberg D, Boonen S et al (2008) Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 58:1687-1695 (Pubitemid 351847521)
6. Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women, with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin. Endocrinol Metab 90:2816-2822 (Pubitemid 40686329)
7. Seeman E, Devogelaer JP, Lorenc R et al (2008) Strontium ranelate reduces the risk, of vertebral fractures in. patients with. osteopenia. J Bone Miner Res 23:433-438 (Pubitemid 351304674)
Hoffmann C, Graf von der Schulenburg JM (2000) The influence of economic evaluation studies on. decision making. A. European survey. The EUROMET group. Health Policy 52:179-192
Drummond M, Dubois D, Garattini L et al (1999) Current trends in the use of pharmacoeconomics and outcomes research in europe. Value Health 2:323-332
Hiligsmann M, Ethgen O, Bruyère O, et al (2009) Development and validation, of a Markov microsimulation model for the economic evaluation of treatments in. osteoporosis. Value Health, doi: 10.1111/ j.1524-4733.2008.00497
Cleemput I, Crott R, Vrijens F et al (2008) Recommandations provisoires pour les évaluations pharmacoéconomiques en Belgique. Health Technology Assessment (HTA). Bruxelles: Centre Fédéral d'Expertise des Soins de Santé (KCE). KCE reports vol. 78B (D/2008/10.273/24)
12. Dere W, Avouac B, Boers M et al (1998) Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcif Tissue Int 63:93-97 (Pubitemid 28347679)
13. Reginster JY, Gillet P, Ben Sedrine W et al (1999) Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 15:507-514 (Pubitemid 29210953)
14. Autier P, Haentjens P, Bentin J et al (2000) Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 11:373-380 (Pubitemid 30450118)
15. Reginster JY, Gillet P, Gosset C (2001) Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Bull World Health. Organ 79:942-946 (Pubitemid 33027173)
Gabriel SE, Tosteson AN, Leibson CL et al (2002) Direct medical, costs attributable to osteoporotic fractures. Osteoporos Int 13:323-330
Melton LJ 3rd, Gabriel SE, Crowson CS et al (2003) Costequivalence of different osteoporotic fractures. Osteoporos Int 14:383-388
Hiligsmann M, Ethgen O, Richy F et al (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82:288-292
Hiligsmann M, Bruyère O, Ethgen O et al (2008) Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 43:991-994
20. Kanis JA, Johnell O, Oden A et al (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585-590 (Pubitemid 30808794)
21. Looker AC, Wanner HW, Dunn WL et al (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468-489 (Pubitemid 28486716)
22. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259 (Pubitemid 26147662)
23. Johnell O, Kanis JA, Oden A et al (2005) Predictive value of BMD for hip and other fractures. J Bone Miner Res 20:1185-1194 (Pubitemid 40863806)
Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739
25. Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375-382 (Pubitemid 38953182)
26. Caulin F, Kanis JA, Johnell O et al (2002) Optimal age for preventing osteoporosis after menopause depends on effects of stopping treatment. Bone 30:754-758 (Pubitemid 34467998)
27. Jonsson B, Kanis J, Dawson A et al (1999) Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int 10:193-199 (Pubitemid 29458713)
Meunier PJ, Roux C, Ortolani S et al (2008) Effects of long-term strontium ranelate treatment on vertebral, fracture risk in postmenopausal women with osteoporosis, doi: 10.1007/s00198-008-0825-6
29. Zethraeus N, Borgstrom. F, Strom O et al (2007) Costeffectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 18:9-23 (Pubitemid 44885492)
30. Borgstrom F, Jonsson B, Strom O et al (2006) An economic evaluation of strontium ranelate in. the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17:1781-1793 (Pubitemid 44607399)
31. Lekkerkerker F, Kanis JA, Alsayed N et al (2007) Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 18:1311-1317 (Pubitemid 47389473)
Rabenda V, Mertens R, Fabri V et al (2008) Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 19:811-818
33. Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44-47 (Pubitemid 351160875)
Belgian Center for Pharmacotherapeutic Information, 2008, Available from:http://www.cbip.be/GGR/MPG/MPG-NJ.cfm#MP-2583
Kanis J, Burlet N, Cooper C et al (2008) European guidance for the diagnosis and. management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-1128
Briggs A, Sculpher M, Claxton. K (2006) Modelling methods for health economic evaluation. Oxford University Press, New York
Neuprez A, Hiligsmann M, Scholtissen S et al (2008) Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Adv Ther 25:1235-1256
Cleemput I, Neyt M, Thiry N et al (2008) Valeurs seuils pour le rapport coût-efficacité en soins de santé. Health Technology Assessment (HTA). Bruxelles: Centre fédéral d'expertise des soins de santé (KCE);2008. KCE Reports 100.B (D/2008/10,273/95)
Raftery J (2001) NICE: faster access to moder treatments? Analysis of guidance on health technologies. Br Med J 323:1300-1303
40. Strom O, Borgstrom F, Sen SS et al (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal, women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos Int 18:1047-1061 (Pubitemid 47020004)
41. Borgstrom F, Johnell O, Kanis JA et al (2004) Cost effectiveness of raloxifene in. the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22:1153-1165 (Pubitemid 39665345)
Kanis JA, Adams J, Borgstrom. F et al (2008) The costeffectiveness of alendronate in the management of osteoporosis. Bone 42:4-15
Stevenson. M, Lloyd Jones M, De Nigris E et al (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1-160
Borgstrom F, Kanis JA (2008) Health economics of osteoporosis. Best Pract Res Clin Endocrinol Metab 22:885-900
45. Al MJ, Feenstra T, Brouwer WB (2004) Decision makers' views on health care objectives and budget constraints: results from, a pilot study. Health Policy 70:33-48 (Pubitemid 39092958)
46. Mauskopf JA, Sullivan SD, Annemans L et al (2007) Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 10:336-347 (Pubitemid 47481105)
47. Bruyere O, Delferriere D, Roux. C et al. (2008) Effects of strontium ranelate on. spinal osteoarthritis progression. Ann Rheum Dis 67:335-339 (Pubitemid 351281267)
Marquis P, Roux C, de la Loge C et al (2008) Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int 19:503-510
Roux C, Fechtenbaum J, Kolta S et al (2008) Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with, severe osteoporosis. Ann. Rheum Dis 67:335-339
Drummond M, Barbieri M, Cook J et al (2009) Transferability of economic evaluations across juridictions: ISPOR good research practices task force report. Value Health [Epub Ahead of Print]